CytomX Therapeutics CTMX
NASDAQ CTMX
$2.42 -0.09 (-3.59%)
As of: Oct 21, 2026 · 3:39 PM EDT

CytomX Therapeutics (CTMX) Construction in Progress (2017 - 2023)

Updated

CytomX Therapeutics' Construction in Progress came in at $368,000 for Q4 2023, down 47.8% from $705,000 a year earlier.

Analysis

CytomX Therapeutics (CTMX) Construction in Progress (2017 - 2023) Analysis & Trends

Going back to Q4 2017, CytomX Therapeutics' Construction in Progress data covers 7 quarters.

  • Construction in Progress carries a five-year compound annual growth rate of -14.1% (FY2018 to FY2023).
  • Going back by year, Construction in Progress was $705,000 in FY2022 (+128.9%), $308,000 in FY2021 (+22.2%), $252,000 in FY2020 (+6.8%) and $236,000 in FY2019 (-69.9%).
  • The Q4 2023 figure represents the lowest quarterly Construction in Progress since Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Eli Lilly 1,137.42 Bn 1,106.00 Bn 19.71 Bn -
2 Johnson & Johnson 617.98 Bn 536.51 Bn 17.26 Bn -
3 AbbVie 502.80 Bn 475.92 Bn 12.70 Bn -
4 Merck 368.67 Bn 323.05 Bn 12.21 Bn -
5 Novartis Ag 298.36 Bn 262.35 Bn 11.24 Bn -
6 Astrazeneca 261.17 Bn 234.85 Bn 12.86 Bn -
7 Amgen 237.18 Bn 192.58 Bn 7.24 Bn -
8 Gilead Sciences 191.11 Bn 165.31 Bn 6.22 Bn -
9 Pfizer 169.83 Bn 116.48 Bn 10.94 Bn -
10 CytomX Therapeutics 530.93 Mn -426.74 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 368,000.00
Dec 31, 2022 705,000.00
Dec 31, 2021 308,000.00
Dec 31, 2020 252,000.00
Dec 31, 2019 236,000.00
Dec 31, 2018 785,000.00
Dec 31, 2017 23,000.00
API Access

CytomX Therapeutics Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=CTMX&period=max&api_key=YOUR_API_KEY